The Technical Analyst
ViewRay Inc [VRAY]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
ViewRay Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0250
America/New_York / 4 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4.59 mill |
| EPS: | -0.260 |
| P/E: | -0.100 |
| Earnings Date: | Oct 29, 2023 |
| SharesOutstanding: | 183.40 mill |
| Avg Daily Volume: | 0 mill |
| RATING 2023-08-21 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.100 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.100 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ -0.0530 - 0.0810 ( +/- 478.57%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-07-15 | Shah Sanket | Buy | 350 000 | Common Stock |
| 2023-07-21 | Shah Sanket | Sell | 30 364 | Common Stock |
| 2023-07-15 | Podbelski Adam Andrew | Buy | 350 000 | Common Stock |
| 2023-07-17 | Podbelski Adam Andrew | Sell | 89 901 | Common Stock |
| 2023-07-15 | Shah Sanket | Sell | 0 | Common Stock |
| INSIDER POWER |
|---|
| -58.50 |
| Last 87 transactions |
| Buy: 4 410 866 | Sell: 16 363 019 |
Forecast:
01:40 - $-0.618
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0250 (0.00% ) |
| Volume | 96.17 mill |
| Avg. Vol. | 0 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VRAY
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
VRAY
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, France, Taiwan, the United Kingdom, and internationally. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. The company was founded in 2004 and is headquartered in Oakwood, Ohio.
Last 10 Buy Signals
Latest Press Releases
2023-10-18 17:03:00 - Press Release
Open Letter To Viewray Customers, Service, Software Engineers And Suppliers—let's Preserve Viewray Technology
Washington--(business wire)--in light of viewray systems recent announcement that it would close its doors on october 25, 2023, dr. suthanthiran, president/founder of teambest global companies (tbg) and best cure foundation, is encouraging all to share their thoughts as to how to preserve, upgrade, innovate, and reduce the cost of technology, service, etc., of viewray systems products—for now and in the future. suthanthiran has already received numerous inquiries from customers, vendors, and se.
2023-10-17 09:04:00 - Press Release
Letter To Viewray Lenders/investment Bankers And Customers From Krishnan Suthanthiran, President/founder Of Teambest Global Companies
Washington--(business wire)--since the announcement regarding the closing of viewray on october 25, 2023, competitors have raced to decommission the viewray systems, replacing them with their own products by establishing relationships with companies that service/decommission/sell refurbished or used equipment—making time of the essence to preserve this valuable technology. while competitors may be motivated to remove viewray's systems and offer alternatives, there's a real possibility that the.
2023-10-13 10:46:00 - Press Release
Open Letter To Viewray Customers From Krishnan Suthanthiran, President/founder Of Teambest Global Companies
Washington--(business wire)--krishnan suthanthiran offers a solution for continued support and service to viewray customers.
2023-07-21 16:01:00 - Press Release
Viewray® Announces Commencement Of Nasdaq Delisting Proceedings: Common Stock Expected To Begin Trading On The Otc Markets
Denver , july 21, 2023 /prnewswire/ -- viewray, inc. (the "company") (nasdaq: vray) announced today that on july 17, it received a letter from the listing qualifications department of the nasdaq stock market llc ("nasdaq"). nasdaq has determined that due to the company's voluntary petition for relief under chapter 11 of the u.s. bankruptcy code, and concerns about the company's ability to sustain compliance with the $1.00 per share minimum bid price requirement for continued inclusion on nasdaq based on listing rule 5450(a)(1), the company's securities will be delisted from the nasdaq stock market.
2023-07-17 07:00:00 - Press Release
Viewray® Files Voluntary Chapter 11 Petitions
Debtor-in-possession financing secured to support ongoing operations and chapter 11 process denver , july 17, 2023 /prnewswire/ -- viewray, inc. (nasdaq: vray) announced today that it and certain of its subsidiaries (collectively, "the company") filed voluntary petitions for relief (the "petitions") under chapter 11 of title 11 the u.s. bankruptcy code ("chapter 11") in the united states bankruptcy court for the district of delaware (the "court"). the company further disclosed that it intends to pursue a sale of its business under section 363 of the bankruptcy code, including a sale of all or a portion of the company's assets, while continuing to support its customers during the chapter 11 process.
Latest News
2023-07-17 10:41:27 - InvestorPlace
Why Is ViewRay (VRAY) Stock Down 69% Today?
ViewRay (NASDAQ: VRAY ) stock is falling hard on Monday after the MRI company announced its voluntary Chapter 11 bankruptcy filing! According to the company's bankruptcy filing, ViewRay intends to pursue the sale of its business as part of the Chapter 11 process.
2023-05-26 08:56:51 - Benzinga
Top 5 Health Care Stocks That Could Blast Off In May - Coherus BioSciences (NASDAQ:CHRS), Intercept Pharma (NASDAQ:ICPT)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
2023-05-10 18:59:41 - Zacks Investment Research
ViewRay (VRAY) Reports Q1 Loss, Misses Revenue Estimates
ViewRay (VRAY) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.14 per share a year ago.
2023-04-13 19:28:13 - Seeking Alpha
ViewRay: Shares Crater As Company Warns Of Slower Growth, Higher Cash Burn
Magnetic resonance imaging-guided radiation therapy system provider ViewRay, Inc. has shocked investors with a severe revenue and cash flow warning. Expected 2023 revenue growth range slashed from a range of 25% to 40% to a new range of 0% to 15%.
2023-04-12 17:25:00 - PRNewsWire
ViewRay Announces Conference Call for Preliminary First Quarter 2023 Financial Results to be held Pre-Market opening on April 13, 2023
DENVER , April 12, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) will hold a conference call to discuss results on Thursday, April 13, 2023, at 8:00 AM ET. The dial-in number for domestic callers is (888) 886-7786.
2023-03-31 11:16:25 - PennyStocks
Penny Stocks To Buy Now? 7 With Unusual Options Volume This Week
2023-02-27 20:42:05 - Seeking Alpha
ViewRay, Inc. (VRAY) Q4 2022 Earnings Call Transcript
ViewRay, Inc. (NASDAQ:VRAY ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Matt Harrison - Director of IR Scott Drake - President and CEO Bill Burke - CFO Conference Call Participants Rick Wise - Stifel Jason Bednar - Piper Sandler Chris Pasquale - Nephron Research Suraj Kalia - Oppenheimer Operator Good afternoon, ladies and gentlemen. And welcome to the ViewRay Q4 2022 Earnings Call.
2023-02-27 19:34:20 - Zacks Investment Research
ViewRay (VRAY) Reports Q4 Loss, Misses Revenue Estimates
ViewRay (VRAY) delivered earnings and revenue surprises of 6.25% and 0.71%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
2023-02-12 23:32:46 - Seeking Alpha
ViewRay: Sales, Order Momentum Ratcheting Higher
ViewRay has continued growth in order momentum. Its stock price has moved sideways into the new year, adding another attractive entry point.
2023-01-31 06:30:00 - PRNewsWire
ViewRay Announces Conference Call for Fourth Quarter 2022 Financial Results to be Held After Market on February 27, 2023
DENVER , Jan. 31, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today details relating to the release of fourth quarter 2022 financial results. ViewRay will hold a conference call to discuss results on Monday, February 27, 2023 at 4:30 p.m.